Cargando…
Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C
BACKGROUND/AIMS: This study was performed to evaluate the efficacy of direct-acting antivirals (DAAs) in Korean patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) and to investigate the risk factors associated with HCC recurrence. METHODS: A total of 100 patients with HCV-r...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editorial Office of Gut and Liver
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129654/ https://www.ncbi.nlm.nih.gov/pubmed/32893194 http://dx.doi.org/10.5009/gnl20151 |
_version_ | 1783694343079460864 |
---|---|
author | Ahn, Young-Hwan Lee, Heirim Kim, Do Young Lee, Hye Won Yu, Su Jong Cho, Young Youn Jang, Jeong Won Jang, Byoung Kuk Kim, Chang Wook Kim, Hee Yeon Park, Hana Cho, Hyo Jung Park, Bumhee Kim, Soon Sun Cheong, Jae Youn |
author_facet | Ahn, Young-Hwan Lee, Heirim Kim, Do Young Lee, Hye Won Yu, Su Jong Cho, Young Youn Jang, Jeong Won Jang, Byoung Kuk Kim, Chang Wook Kim, Hee Yeon Park, Hana Cho, Hyo Jung Park, Bumhee Kim, Soon Sun Cheong, Jae Youn |
author_sort | Ahn, Young-Hwan |
collection | PubMed |
description | BACKGROUND/AIMS: This study was performed to evaluate the efficacy of direct-acting antivirals (DAAs) in Korean patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) and to investigate the risk factors associated with HCC recurrence. METHODS: A total of 100 patients with HCV-related HCC, who were treated with DAAs between May 2015 and December 2016, were recruited from seven university hospitals in Korea. Claim data of 526 patients with HCC obtained from the Health Insurance Review and Assessment Service in South Korea were used for external validation of the results. RESULTS: Among the 100 patients, 88% achieved a sustained virological response (SVR) 12 weeks after the end of DAA therapy (SVR12), and 37% experienced HCC recurrence after DAA therapy. Short last HCC treatment durability (<12 months) before DAA commencement was independently associated with HCC recurrence (hazard ratio [HR], 2.89; p=0.011). In the nationwide validation cohort, 20.3% of the patients experienced HCC recurrence. The last HCC treatment with a noncurative method, a short last HCC treatment durability (<12 months), and a longer total duration of HCC treatment (≥18 months) were independently related with HCC recurrence (HR 3.73, p<0.001; HR 3.34, p<0.001; and HR 1.74, p=0.006; respectively). CONCLUSIONS: DAA therapy showed an acceptable SVR12 rate in patients with HCV-related HCC. Short last HCC treatment durability (<12 months) was associated with HCC recurrence after DAA therapy. This finding suggests that the last HCC treatment durability is an important predictor of HCC recurrence after DAA therapy. (Gut Liver 2021;15-419) |
format | Online Article Text |
id | pubmed-8129654 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Editorial Office of Gut and Liver |
record_format | MEDLINE/PubMed |
spelling | pubmed-81296542021-05-24 Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C Ahn, Young-Hwan Lee, Heirim Kim, Do Young Lee, Hye Won Yu, Su Jong Cho, Young Youn Jang, Jeong Won Jang, Byoung Kuk Kim, Chang Wook Kim, Hee Yeon Park, Hana Cho, Hyo Jung Park, Bumhee Kim, Soon Sun Cheong, Jae Youn Gut Liver Original Article BACKGROUND/AIMS: This study was performed to evaluate the efficacy of direct-acting antivirals (DAAs) in Korean patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) and to investigate the risk factors associated with HCC recurrence. METHODS: A total of 100 patients with HCV-related HCC, who were treated with DAAs between May 2015 and December 2016, were recruited from seven university hospitals in Korea. Claim data of 526 patients with HCC obtained from the Health Insurance Review and Assessment Service in South Korea were used for external validation of the results. RESULTS: Among the 100 patients, 88% achieved a sustained virological response (SVR) 12 weeks after the end of DAA therapy (SVR12), and 37% experienced HCC recurrence after DAA therapy. Short last HCC treatment durability (<12 months) before DAA commencement was independently associated with HCC recurrence (hazard ratio [HR], 2.89; p=0.011). In the nationwide validation cohort, 20.3% of the patients experienced HCC recurrence. The last HCC treatment with a noncurative method, a short last HCC treatment durability (<12 months), and a longer total duration of HCC treatment (≥18 months) were independently related with HCC recurrence (HR 3.73, p<0.001; HR 3.34, p<0.001; and HR 1.74, p=0.006; respectively). CONCLUSIONS: DAA therapy showed an acceptable SVR12 rate in patients with HCV-related HCC. Short last HCC treatment durability (<12 months) was associated with HCC recurrence after DAA therapy. This finding suggests that the last HCC treatment durability is an important predictor of HCC recurrence after DAA therapy. (Gut Liver 2021;15-419) Editorial Office of Gut and Liver 2021-05-15 2020-09-09 /pmc/articles/PMC8129654/ /pubmed/32893194 http://dx.doi.org/10.5009/gnl20151 Text en Copyright © Gut and Liver. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Ahn, Young-Hwan Lee, Heirim Kim, Do Young Lee, Hye Won Yu, Su Jong Cho, Young Youn Jang, Jeong Won Jang, Byoung Kuk Kim, Chang Wook Kim, Hee Yeon Park, Hana Cho, Hyo Jung Park, Bumhee Kim, Soon Sun Cheong, Jae Youn Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C |
title | Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C |
title_full | Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C |
title_fullStr | Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C |
title_full_unstemmed | Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C |
title_short | Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C |
title_sort | independent risk factors for hepatocellular carcinoma recurrence after direct-acting antiviral therapy in patients with chronic hepatitis c |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129654/ https://www.ncbi.nlm.nih.gov/pubmed/32893194 http://dx.doi.org/10.5009/gnl20151 |
work_keys_str_mv | AT ahnyounghwan independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc AT leeheirim independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc AT kimdoyoung independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc AT leehyewon independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc AT yusujong independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc AT choyoungyoun independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc AT jangjeongwon independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc AT jangbyoungkuk independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc AT kimchangwook independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc AT kimheeyeon independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc AT parkhana independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc AT chohyojung independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc AT parkbumhee independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc AT kimsoonsun independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc AT cheongjaeyoun independentriskfactorsforhepatocellularcarcinomarecurrenceafterdirectactingantiviraltherapyinpatientswithchronichepatitisc |